Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 67
Filtrar
1.
J Antimicrob Chemother ; 76(3): 635-638, 2021 02 11.
Artigo em Inglês | MEDLINE | ID: mdl-33374010

RESUMO

BACKGROUND: The performance of the galactomannan enzyme immunoassay (GM-EIA) is impaired in patients receiving mould-active antifungal therapy. The impact of mould-active antifungal therapy on Aspergillus PCR testing needs to be determined. OBJECTIVES: To determine the influence of anti-mould prophylaxis (AMP) on the performance of PCR blood testing to aid the diagnosis of proven/probable invasive aspergillosis (IA). METHODS: As part of the systematic review and meta-analysis of 22 cohort studies investigating Aspergillus PCR blood testing in 2912 patients at risk of IA, subgroup analysis was performed to determine the impact of AMP on the accuracy of Aspergillus PCR. The incidence of IA was calculated in patients receiving and not receiving AMP. The impact of two different positivity thresholds (requiring either a single PCR positive test result or ≥2 consecutive PCR positive test results) on accuracy was evaluated. Meta-analytical pooling of sensitivity and specificity was performed by logistic mixed-model regression. RESULTS: In total, 1661 (57%) patients received prophylaxis. The incidence of IA was 14.2%, significantly lower in the prophylaxis group (11%-12%) compared with the non-prophylaxis group (18%-19%) (P < 0.001). The use of AMP did not affect sensitivity, but significantly decreased specificity [single PCR positive result threshold: 26% reduction (P = 0.005); ≥2 consecutive PCR positive results threshold: 12% reduction (P = 0.019)]. CONCLUSIONS: Contrary to its influence on GM-EIA, AMP significantly decreases Aspergillus PCR specificity, without affecting sensitivity, possibly as a consequence of AMP limiting the clinical progression of IA and/or leading to false-negative GM-EIA results, preventing the classification of probable IA using the EORTC/MSGERC definitions.


Assuntos
Aspergilose , Infecções Fúngicas Invasivas , Aspergilose/diagnóstico , Aspergilose/prevenção & controle , Aspergillus/genética , Humanos , Mananas , Metanálise como Assunto , Reação em Cadeia da Polimerase , Sensibilidade e Especificidade
2.
Med Mycol ; 59(2): 126-138, 2021 Feb 04.
Artigo em Inglês | MEDLINE | ID: mdl-32534456

RESUMO

Interlaboratory evaluations of Mucorales qPCR assays were developed to assess the reproducibility and performance of methods currently used. The participants comprised 12 laboratories from French university hospitals (nine of them participating in the Modimucor study) and 11 laboratories participating in the Fungal PCR Initiative. For panel 1, three sera were each spiked with DNA from three different species (Rhizomucor pusillus, Lichtheimia corymbifera, Rhizopus oryzae). For panel 2, six sera with three concentrations of R. pusillus and L. corymbifera (1, 10, and 100 genomes/ml) were prepared. Each panel included a blind negative-control serum. A form was distributed with each panel to collect results and required technical information, including DNA extraction method, sample volume used, DNA elution volume, qPCR method, qPCR template input volume, qPCR total reaction volume, qPCR platform, and qPCR reagents used. For panel 1, assessing 18 different protocols, qualitative results (positive or negative) were correct in 97% of cases (70/72). A very low interlaboratory variability in Cq values (SD = 1.89 cycles) were observed. For panel 2 assessing 26 different protocols, the detection rates were high (77-100%) for 5/6 of spiked serum. There was a significant association between the qPCR platform and performance. However, certain technical steps and optimal combinations of factors may also impact performance. The good reproducibility and performance demonstrated in this study support the use of Mucorales qPCR as part of the diagnostic strategy for mucormycosis.


Assuntos
Técnicas de Laboratório Clínico/normas , DNA Fúngico/genética , Técnicas de Diagnóstico Molecular/normas , Mucorales/genética , Mucormicose/sangue , Mucormicose/diagnóstico , Reação em Cadeia da Polimerase em Tempo Real/normas , Técnicas de Laboratório Clínico/instrumentação , Técnicas de Laboratório Clínico/métodos , França , Hospitais Universitários/estatística & dados numéricos , Humanos , Variações Dependentes do Observador , Reprodutibilidade dos Testes
3.
Clin Microbiol Infect ; 24 Suppl 1: e1-e38, 2018 May.
Artigo em Inglês | MEDLINE | ID: mdl-29544767

RESUMO

The European Society for Clinical Microbiology and Infectious Diseases, the European Confederation of Medical Mycology and the European Respiratory Society Joint Clinical Guidelines focus on diagnosis and management of aspergillosis. Of the numerous recommendations, a few are summarized here. Chest computed tomography as well as bronchoscopy with bronchoalveolar lavage (BAL) in patients with suspicion of pulmonary invasive aspergillosis (IA) are strongly recommended. For diagnosis, direct microscopy, preferably using optical brighteners, histopathology and culture are strongly recommended. Serum and BAL galactomannan measures are recommended as markers for the diagnosis of IA. PCR should be considered in conjunction with other diagnostic tests. Pathogen identification to species complex level is strongly recommended for all clinically relevant Aspergillus isolates; antifungal susceptibility testing should be performed in patients with invasive disease in regions with resistance found in contemporary surveillance programmes. Isavuconazole and voriconazole are the preferred agents for first-line treatment of pulmonary IA, whereas liposomal amphotericin B is moderately supported. Combinations of antifungals as primary treatment options are not recommended. Therapeutic drug monitoring is strongly recommended for patients receiving posaconazole suspension or any form of voriconazole for IA treatment, and in refractory disease, where a personalized approach considering reversal of predisposing factors, switching drug class and surgical intervention is also strongly recommended. Primary prophylaxis with posaconazole is strongly recommended in patients with acute myelogenous leukaemia or myelodysplastic syndrome receiving induction chemotherapy. Secondary prophylaxis is strongly recommended in high-risk patients. We strongly recommend treatment duration based on clinical improvement, degree of immunosuppression and response on imaging.


Assuntos
Antifúngicos/uso terapêutico , Aspergilose/diagnóstico , Aspergilose/tratamento farmacológico , Aspergillus/isolamento & purificação , Gerenciamento Clínico , Anticorpos Antifúngicos/sangue , Antifúngicos/farmacologia , Aspergilose/complicações , Aspergilose/imunologia , Aspergillus/efeitos dos fármacos , Aspergillus/imunologia , Biópsia/métodos , Lavagem Broncoalveolar , Diagnóstico Precoce , Flucitosina/farmacologia , Flucitosina/uso terapêutico , Galactose/análogos & derivados , Humanos , Hospedeiro Imunocomprometido , Testes Imunológicos , Aspergilose Pulmonar Invasiva/diagnóstico , Itraconazol/farmacologia , Itraconazol/uso terapêutico , Leucemia Mieloide Aguda/complicações , Leucemia Mieloide Aguda/terapia , Imageamento por Ressonância Magnética , Mananas/análise , Testes de Sensibilidade Microbiana , Síndromes Mielodisplásicas/complicações , Síndromes Mielodisplásicas/terapia , Nitrilas/farmacologia , Nitrilas/uso terapêutico , Piridinas/farmacologia , Piridinas/uso terapêutico , Tomografia Computadorizada por Raios X , Triazóis/farmacologia , Triazóis/uso terapêutico , Voriconazol/farmacologia , Voriconazol/uso terapêutico
4.
Mar Pollut Bull ; 98(1-2): 372-4, 2015 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-26277603
6.
Med Mycol Case Rep ; 4: 26-9, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24855598

RESUMO

Scedosporium prolificans are opportunistic moulds that can cause mycetoma following penetrating injuries. This fungus is more virulent than other species and treatment options are limited. Here we describe the first known case in the UK of S. prolificans osteomyelitis, in a 4 year old following penetrating injury. Successful outcome with limb salvage and foot function is achieved after repeated surgical debridement, and combination chemotherapy with voriconazole/terbinafine.

7.
Diabet Med ; 30(9): 1040-6, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23551273

RESUMO

AIM: To identify predictors of large and small for gestational age in women with gestational diabetes mellitus. METHODS: A retrospective audit of clinical data analysed for singleton births in women diagnosed with gestational diabetes by Australasian Diabetes in Pregnancy Society guidelines from 1994 to 2009. Exclusions were: incomplete data, delivered at < 36 weeks gestation and/or last recorded weight > 4 weeks pre-delivery. We assessed: pre-pregnancy BMI, ethnicity, total maternal weight gain, weight gain before and after treatment initiation for gestational diabetes, HbA(1c) at gestational diabetes presentation and treatment modality (diet or insulin) and smoking. Birthweight was assessed using customized percentile charts (large for gestational age > 90th; small for gestational age < 10th percentile). Multiple regression analyses were undertaken; statistical significance was p < 0.05. RESULTS: There were 1695 women first seen at (mean ± sd) 28.1 ± 5.3 weeks gestation (range 6-39). Ethnic mix was South-East Asian 36.7%, Middle Eastern 27.6%, European 22.4%, Indian/Pakistani 8.6%, Samoan 1.9%, African 1.5% and Maori 1.1%. Therapy was diet 69.1% and insulin 30.9%. Mean total weight gain was 12.3 ± 6.1 kg, the majority (10.6 ± 6.0 kg), gained before dietary intervention. There were 7.9% small for gestational age and 15.2% large for gestational age births. Significant independent large for gestational age predictors were: weight gain before intervention, pre-pregnancy BMI, weight gain after intervention and treatment type, but not HbA1c or smoking. Significant small for gestational age predictors were: weight gain before intervention, weight gain after intervention, but not pre-pregnancy BMI, HbA(1c) or smoking. CONCLUSION: Conventional treatment for gestational diabetes mellitus concentrates on management of blood glucose levels. The trends identified here emphasize the need to also address pregnancy weight gain stratified by pre-pregnancy BMI.


Assuntos
Diabetes Gestacional/fisiopatologia , Retardo do Crescimento Fetal/etiologia , Macrossomia Fetal/etiologia , Obesidade/complicações , Sobrepeso/complicações , Magreza/complicações , Animais , Australásia/epidemiologia , Peso ao Nascer , Índice de Massa Corporal , Diabetes Gestacional/terapia , Feminino , Retardo do Crescimento Fetal/epidemiologia , Macrossomia Fetal/epidemiologia , Humanos , Incidência , Recém-Nascido , Recém-Nascido Pequeno para a Idade Gestacional , Masculino , Gravidez , Prevalência , Estudos Retrospectivos , Fatores de Risco , Fumar/efeitos adversos , Aumento de Peso
8.
Intensive Care Med ; 35(11): 1970-3, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19644673

RESUMO

OBJECTIVE: Surgical tracheostomy in critically ill adults has largely been replaced by physicians performing percutaneous dilatational tracheostomy (PDT) at the bedside. Complications associated with this technique include haemorrhage, wound infection, barotrauma, false passage, ruptured tracheal ring and bacteraemia. Prophylactic antibiotics are not generally used with this procedure, however the incidence of bacteraemia following PDT has not been extensively studied. DESIGN: Prospective observational study. SETTING: Adult intensive care unit of a university medical centre. METHODS: Peripheral venous blood cultures were obtained immediately before and after PDT in 118 consecutive patients. Surveillance cultures of potential respiratory pathogens were also recorded using routine non-directed broncholalveolar lavage. RESULTS: Forty-three female and 75 male patients underwent PDT. Fifty-seven patients (48.3%) were not receiving antibiotics on the day of PDT, whilst the remaining 61 individuals (51.7%) were on antibiotic therapy at the time of the procedure. Bacteraemia following PDT occurred in six out of 113 patients (5.3%), five of which occurred in patients not receiving antibiotics (9.2%). Unexpected bacteraemia (positive pre-and post PDT blood cultures) was identified in five patients, two of whom were on antibiotic therapy. CONCLUSION: The incidence of bacteraemia following a single stage PDT was similar to other manipulations of the aerodigestive tract such as intubation, insertion of an LMA or tooth brushing. We suggest that routine antibiotic prophylaxis is unnecessary for this procedure.


Assuntos
Bacteriemia/etiologia , Infecção Hospitalar/etiologia , Dilatação/efeitos adversos , Traqueostomia/efeitos adversos , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibioticoprofilaxia/estatística & dados numéricos , Bacteriemia/diagnóstico , Bacteriemia/epidemiologia , Bacteriemia/prevenção & controle , Cuidados Críticos , Infecção Hospitalar/diagnóstico , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/prevenção & controle , Dilatação/instrumentação , Feminino , Hospitais Universitários , Humanos , Incidência , Controle de Infecções , Masculino , Pessoa de Meia-Idade , Quartos de Pacientes , Sistemas Automatizados de Assistência Junto ao Leito , Estudos Prospectivos , Fatores de Risco , Traqueostomia/instrumentação , País de Gales/epidemiologia
9.
J Infect ; 58(2): 145-53, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19185349

RESUMO

OBJECTIVE: The objective of this study was to audit the compliance and implementation of the British Society for Medical Mycology standards of care for patients with invasive infections in UK hospitals. METHODS: A multidisciplinary audit questionnaire regarding the processing of microbiology and histopathology specimens, radiology imaging and clinical management of patients with invasive fungal infections was distributed to UK hospitals. RESULTS: The study has shown that speciation of Candida and Aspergillus isolates from sterile sites was performed in 42-98% of hospitals. Microscopy of bronchoscopy specimens was not undertaken in 13 of 62 (21%) laboratories. Cryptococcal culture and antigen were undertaken routinely in abnormal CSF in 40-75% and 31-83% of at-risk patients but only in 12% of abnormal CSFs in patients without risk factors. Detailed fungal morphology was provided by <50% of histopathology departments. Most hospitals provided a timely HRCT or MRI on patients suspected to have an invasive fungal infection, but early treatment failed to occur in 15% of hospitals. In patients presenting with candidaemia, central venous catheters (CVC) were not changed routinely within 48h in 15%. CONCLUSION: Improvement in microbiology and histopathology specimen processing as well as rapid interventions such as initiation of anti-fungal therapy or CVC line removal could improve diagnostic rates and clinical outcomes of invasive fungal infections.


Assuntos
Pesquisa sobre Serviços de Saúde , Micoses/diagnóstico , Micoses/tratamento farmacológico , Fungos/classificação , Fungos/isolamento & purificação , Humanos , Micoses/microbiologia , Inquéritos e Questionários , Reino Unido
10.
J Clin Pathol ; 62(1): 64-9, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19103864

RESUMO

AIMS: To investigate the impact of routine use of biomarkers for diagnosing fungal infection within a care pathway on antifungal usage and clinical outcomes. METHODS: A cohort of high-risk haematology and stem cell transplant patients was entered into a neutropenic care pathway in which targeted diagnostic testing replaced empiric antifungal treatment. Patients were screened twice a week by PCR and antigen testing during fever or when chronic graft versus host disease was present and were followed-up for a minimum of 1 year. RESULTS: No excess morbidity or mortality was seen in patients in whom empiric antifungal treatment was withheld, and there were substantial savings in antifungal drug expenditure. CONCLUSIONS: The introduction of a comprehensive diagnostic surveillance strategy to exclude invasive fungal infection in high-risk patients with haematological malignancy and those undergoing transplantation can result in improvements in clinical management. There are also potential additional benefits of improved patient survival, decreased morbidity and decreased hospital stay.


Assuntos
Neoplasias Hematológicas/complicações , Micoses/diagnóstico , Infecções Oportunistas/diagnóstico , Transplante de Células-Tronco/efeitos adversos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antifúngicos/administração & dosagem , Aspergilose/complicações , Aspergilose/diagnóstico , Aspergilose/imunologia , Biomarcadores/análise , Candidíase/complicações , Candidíase/diagnóstico , Candidíase/imunologia , Procedimentos Clínicos , Métodos Epidemiológicos , Feminino , Humanos , Hospedeiro Imunocomprometido , Masculino , Pessoa de Meia-Idade , Micoses/complicações , Micoses/imunologia , Infecções Oportunistas/complicações , Infecções Oportunistas/imunologia , Reação em Cadeia da Polimerase , Adulto Jovem
11.
J Res Natl Inst Stand Technol ; 113(4): 187-203, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-27096120

RESUMO

There is a 5 W/m(2) (about 0.35 %) difference between current on-orbit Total Solar Irradiance (TSI) measurements. On 18-20 July 2005, a workshop was held at the National Institute of Standards and Technology (NIST) in Gaithersburg, Maryland that focused on understanding possible reasons for this difference, through an examination of the instrument designs, calibration approaches, and appropriate measurement equations. The instruments studied in that workshop included the Active Cavity Radiometer Irradiance Monitor III (ACRIM III) on the Active Cavity Radiometer Irradiance Monitor SATellite (ACRIMSAT), the Total Irradiance Monitor (TIM) on the Solar Radiation and Climate Experiment (SORCE), the Variability of solar IRradiance and Gravity Oscillations (VIRGO) on the Solar and Heliospheric Observatory (SOHO), and the Earth Radiation Budget Experiment (ERBE) on the Earth Radiation Budget Satellite (ERBS). Presentations for each instrument included descriptions of its design, its measurement equation and uncertainty budget, and the methods used to assess on-orbit degradation. The workshop also included a session on satellite- and ground-based instrument comparisons and a session on laboratory-based comparisons and the application of new laboratory comparison techniques. The workshop has led to investigations of the effects of diffraction and of aperture area measurements on the differences between instruments. In addition, a laboratory-based instrument comparison is proposed that uses optical power measurements (with lasers that underfill the apertures of the TSI instruments), irradiance measurements (with lasers that overfill the apertures of the TSI instrument), and a cryogenic electrical substitution radiometer as a standard for comparing the instruments. A summary of the workshop and an overview of the proposed research efforts are presented here.

12.
J Chemother ; 19(3): 283-7, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17594923

RESUMO

There are conflicting reports on the agreement between the Clinical and Laboratory Standards Institute disk diffusion (M44-A) and reference broth microdilution (M27-A) methods for determination of antifungal susceptibility of yeasts. The antifungal susceptibility of 541 yeasts, the majority of which were from the oral cavity, was determined using these two methods and the accuracy of the disk diffusion method assessed for clinical testing of various Candida species. Of the strains tested, Candida albicans predominated (390 out of 541). The classification of susceptibility determined by the disk diffusion method was largely in concordance with that obtained using the broth dilution method, regardless of species within Candida genus. The overall observed agreement between these two methods was 94.7% for fluconazole and 96.7% for voriconazole was with a 'very major' discrepancy level of 1.5% and 1.7% respectively. This study demonstrates a strong agreement of the simple disk diffusion method with the more labour intensive 'gold standard' broth microdilution method. These findings would support the use of the disk diffusion method in a routine mycology service.


Assuntos
Antifúngicos/farmacologia , Candida/efeitos dos fármacos , Fluconazol/farmacologia , Técnicas Microbiológicas/métodos , Pirimidinas/farmacologia , Triazóis/farmacologia , Testes de Sensibilidade a Antimicrobianos por Disco-Difusão , Humanos , Testes de Sensibilidade Microbiana , Reprodutibilidade dos Testes , Voriconazol
13.
J Infect ; 51(3): e171-2, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16230200

RESUMO

This report documents a case of sepsis caused by a recently recognized environmental organism and demonstrates the pathogenicity of this bacterium in the clinical setting.


Assuntos
Comamonadaceae/isolamento & purificação , Infecções por Bactérias Gram-Negativas/complicações , Sepse/microbiologia , Sangue/microbiologia , Meios de Cultura , Infecções por Bactérias Gram-Negativas/microbiologia , Humanos , Masculino , Pessoa de Meia-Idade
14.
J Hosp Infect ; 60(1): 78-80, 2005 May.
Artigo em Inglês | MEDLINE | ID: mdl-15823662

RESUMO

This paper describes a simple and rapid method for the differentiation of Candida albicans from other yeast species in primary cultures based on colonial morphology following incubation in carbon dioxide. The technique has superior sensitivity to the traditional germ-tube method and requires no additional laboratory tests. In a busy laboratory, this can result in significant savings in cost and time, as well as improvements in patient care.


Assuntos
Ágar/normas , Candida albicans , Dióxido de Carbono/normas , Meios de Cultura/normas , Temperatura Alta , Técnicas de Tipagem Micológica/métodos , Ágar/economia , Candida albicans/classificação , Candida albicans/citologia , Candida albicans/genética , Candida albicans/isolamento & purificação , Candidíase/diagnóstico , Candidíase/microbiologia , Dióxido de Carbono/economia , Contagem de Colônia Microbiana , Redução de Custos , Meios de Cultura/economia , DNA Fúngico/genética , Diagnóstico Diferencial , Humanos , Técnicas de Tipagem Micológica/economia , Técnicas de Tipagem Micológica/normas , Fenótipo , Sensibilidade e Especificidade , Fatores de Tempo
15.
J Hosp Infect ; 54(1): 18-24, 2003 May.
Artigo em Inglês | MEDLINE | ID: mdl-12767842

RESUMO

This two-year prospective hospital population-based study of candidaemia is the first to be conducted in the UK. It was carried out on behalf on the British Society for Medical Mycology (BSMM) as part of the European Confederation of Medical Mycology (ECMM) epidemiological survey of candidaemia. Six hospitals in England and Wales acted as sentinel hospitals. Main outcome measures were hospital population-based incidence and 30-day mortality. There were 18.7 episodes of candidaemia per 100,000 finished consultant episodes or 3.0/100,000 bed days and 45.4% cases occurred in intensive care unit (ICU) patients. Candida albicans was isolated in 64.7% of confirmed cases. The majority of isolates were sensitive to standard antifungal agents, including fluconazole. The overall 30-day mortality was 26.4% and removal of the central venous catheter was associated with a significant reduction in mortality. In conclusion, the incidence of candidaemia in England and Wales is similar to that of the USA, the majority of isolates remain sensitive to commonly used antifungal agents and mortality associated with this infection appears to be falling.


Assuntos
Antifúngicos/farmacologia , Candida/efeitos dos fármacos , Candidíase/epidemiologia , Avaliação de Resultados em Cuidados de Saúde , Adolescente , Adulto , Distribuição por Idade , Idoso , Idoso de 80 Anos ou mais , Candida/classificação , Candida/isolamento & purificação , Candidíase/etiologia , Candidíase/mortalidade , Candidíase/prevenção & controle , Criança , Pré-Escolar , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/etiologia , Infecção Hospitalar/mortalidade , Infecção Hospitalar/prevenção & controle , Farmacorresistência Fúngica , Inglaterra/epidemiologia , Feminino , Humanos , Incidência , Lactente , Recém-Nascido , Controle de Infecções/métodos , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Estudos Prospectivos , Vigilância de Evento Sentinela , País de Gales/epidemiologia
17.
Appl Opt ; 40(3): 343-8, 2001 Jan 20.
Artigo em Inglês | MEDLINE | ID: mdl-18357007

RESUMO

A simple correction method to remove the spectral bandpass effects of the Sea-viewing Wide Field-of-view Sensor (SeaWiFS) on the derived normalized water-leaving radiances and ocean-near-surface chlorophyll concentration is developed and implemented in the SeaWiFS data-processing system. SeaWiFS has not only in-band response structures but also significant sensor out-of-band contributions. The effects of the SeaWiFS out-of-band contribution at the green bands is particularly significant for the derived normalized water-leaving radiances and therefore for the retrieved ocean-near-surface chlorophyll concentration. With the sensor spectral bandpass corrections, the low chlorophyll concentration is even lower in the clear ocean regions, whereas there are almost no changes for the oceans with a chlorophyll concentration of >0.2 mg/m(3).

18.
Appl Opt ; 40(36): 6682-700, 2001 Dec 20.
Artigo em Inglês | MEDLINE | ID: mdl-18364980

RESUMO

We present an overview of the calibration of the Sea-viewing Wide Field-of View Sensor (SeaWiFS) from its performance verification at the manufacturer's facility to the completion of its third year of on-orbit measurements. These calibration procedures have three principal parts: a prelaunch radiometric calibration that is traceable to the National Institute of Standards and Technology; the Transfer-to-Orbit Experiment, a set of measurements that determine changes in the instrument's calibration from its manufacture to the start of on-orbit operations; and measurements of the sun and the moon to determine radiometric changes on orbit. To our knowledge, SeaWiFS is the only instrument that uses routine lunar measurements to determine changes in its radiometric sensitivity. On the basis of these methods, the overall uncertainty in the SeaWiFS top-of-the-atmosphere radiances is estimated to be 4-5%. We also show the results of comparison campaigns with aircraft- and ground-based measurements, plus the results of an experiment, called the Southern Ocean Band 8 Gain Study. These results are used to check the calibration of the SeaWiFS bands. To date, they have not been used to change the instrument's prelaunch calibration coefficients. In addition to these procedures, SeaWiFS is a vicariously calibrated instrument for ocean-color measurements. In the vicarious calibration of the SeaWiFS visible bands, the calibration coefficients are modified to force agreement with surface truth measurements from the Marine Optical Buoy, which is moored off the Hawaiian Island of Lanai. This vicarious calibration is described in a companion paper.

19.
Appl Opt ; 40(36): 6701-18, 2001 Dec 20.
Artigo em Inglês | MEDLINE | ID: mdl-18364981

RESUMO

We present an overview of the vicarious calibration of the Sea-Viewing Wide Field-of-view Sensor (SeaWiFS). This program has three components: the calibration of the near-infrared bands so that the atmospheric correction algorithm retrieves the optical properties of maritime aerosols in the open ocean; the calibration of the visible bands against in-water measurements from the Marine Optical Buoy (MOBY); and a calibration-verification program that uses comparisons between SeaWiFS retrievals and globally distributed in situ measurements of water-leaving radiances. This paper describes the procedures as implemented for the third reprocessing of the SeaWiFS global mission data set. The uncertainty in the near-infrared vicarious gain is 0.9%. The uncertainties in the visible-band vicarious gains are 0.3%, corresponding to uncertainties in the water-leaving radiances of approximately 3%. The means of the SeaWiFS/in situ matchup ratios for water-leaving radiances are typically within 5% of unity in Case 1 waters, while chlorophyll a ratios are within 1% of unity. SeaWiFS is the first ocean-color mission to use an extensive and ongoing prelaunch and postlaunch calibration program, and the matchup results demonstrate the benefits of a comprehensive approach.

20.
Curr Opin Crit Care ; 7(5): 362-6, 2001 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11805534

RESUMO

Bone marrow transplantation and stem cell transplantation have become standard therapies offering potential cures for a number of hematologic malignancies and immunologic disorders. Severe infection remains a life threatening complication after transplantation, contributes significantly to morbidity, and may necessitate admission to the ICU. It is estimated that between 20 and 40% of patients receiving bone marrow transplant will require ICU admission in the initial posttransplantation phase. Historically, survival rates after admission to the ICU are dismal, particularly if mechanical ventilation is required for respiratory failure. Other organ involvement worsens the prognosis still further and has led to proposals for rationing or restricting access to critical care units and supportive measures. Recent studies have reported small but significant improvements in outcome after critical illness. Whether this improvement is a result of changes in levels of supportive care or a more defined patient selection is uncertain. Moreover, risk factors identifying patients who will benefit most from intensive support are poorly defined. However, it is generally accepted that respiratory failure requiring invasive mechanical ventilation is associated with a poor prognosis in this patient group. Early involvement of intensivists in the management of critical illness in transplant recipients is likely to continue to improve survival in this group of patients.


Assuntos
Transplante de Medula Óssea , Transplante de Medula Óssea/efeitos adversos , Infecções/etiologia , Transplante de Medula Óssea/mortalidade , Humanos , Infecções/diagnóstico , Unidades de Terapia Intensiva , Insuficiência de Múltiplos Órgãos/diagnóstico , Insuficiência de Múltiplos Órgãos/etiologia , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/mortalidade , Prognóstico , Fatores de Risco , Índice de Gravidade de Doença , Taxa de Sobrevida , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...